Havrix 720 Junior

Per 0.5 mL Inactivated HAV 720 ELISA Unit, adsorbed Al hydroxide, hydrated 0.25 mg Al³⁺

Active immunization against HAV infection in subjects at risk of exposure to HAV. In areas of low to intermediate prevalence of hepatitis A, immunization w/ Havrix is particularly recommended in subjects who are, or will be, at increased risk of infection eg, travelers, armed forces, persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission (employees in day-care centres, nursing, medical & paramedical personnel in hospitals & institutions, especially gastroenterology & paed units, sewage workers, food handlers, among others), persons at increased risk due to their sexual behavior, haemophiliacs, abusers of injectable drugs, contacts of infected persons, persons who require protection as part of hepatitis A outbreak control, specific population groups known to have a higher incidence of hepatitis A (American Indians, Eskimos, recognised community-wide HAV epidemics), subjects w/ chronic liver disease or who are at risk of developing chronic liver disease (eg, hepatitis B & hepatitis C chronic carriers & alcohol abusers).

IM Childn & adolescent 1-18 yr 1^st dose: 0.5 mL as primary immunization in deltoid or anterolateral aspect of thigh in young childn. Booster dose is recommended between 6 mth & 5 yr but preferably between 6 & 12 mth after the primary dose.

Hypersensitivity to any component of Havrix or after previous administration of Havrix.

Hypersensitivity to neomycin. Should not be administered in gluteal region or SC/intradermally & intravascularly. Postpone vaccination in patients w/ acute severe febrile illness. Impaired immune system or those on haemodialysis may require additional doses. Does not prevent hepatitis infection caused by other agents eg, HBV, HCV, hepatitis E virus or other pathogens known to infect the liver. Thrombocytopenia or a bleeding disorder. Syncope (fainting) can occur. Pregnancy & lactation.

Irritability; headache; pain & redness at the inj site, fatigue. Loss of appetite; drowsiness; GI symptoms eg, diarrhoea, nausea, vomiting; malaise, fever ≥37.5°C, inj site reaction eg, swelling or induration.

Vaccines, Antisera & Immunologicals

J07BC02 - hepatitis A, inactivated, whole virus ; Belongs to the class of hepatitis viral vaccines.

G